J. P. Garcia

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

Sung-Bae Kim, S. Loi, A. Bardia, 2020 .

Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study

E. Hitre, S. Kümmel, B. Karaszewska, 2020 .

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.